期刊
BLOOD
卷 118, 期 24, 页码 6306-6309出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2011-04-349910
关键词
-
类别
资金
- Fonds National de la Recherche Scientifique
- Televie
- Belgian Foundation against Cancer
- European Union [INCA LSHC-CT-2005-018704]
- Neoangio excellence program
- Partenariat Public Prive PPP INCA of the Direction generale des Technologies
- Walloon government [DG06]
- Communaute francaise de Belgique
- University of Liege
- GxABT (University of Liege)
- Centre anticancereux pres University of Liege
- Service Public Federal
- Medical Research Council [G0601072] Funding Source: researchfish
- MRC [G0601072] Funding Source: UKRI
HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a neurodegenerative disease of the central nervous system induced by human T-lymphotropic virus type 1. As a potential therapeutic approach, we previously suggested reducing the proviral load by modulating lysine deacetylase activity using valproic acid (VPA) and exposing virus-positive cells to the host immune response. We conducted a single-center, 2-year, open-label trial, with 19 HAM/TSP volunteers treated with oral VPA. Proviral load, CD38/HLA-DR expression, and CD8(+) lysis efficiency were not significantly affected by VPA. Mean scores of HAM/TSP disability did not differ between baseline and final visit. Walking Time Test increased significantly (> 20%) in 3 patients and was in keeping with minor VPA side effects (drowsiness and tremor). Walking Time Test improved rapidly after VPA discontinuation. We conclude that long-term treatment with VPA is safe in HAM/TSP. (Blood. 2011; 118(24): 6306-6309)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据